Baillie Gifford & Co’s Exact Sciences EXAS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-763,356
| Closed | -$41.8M | – | 276 |
|
|
2025
Q3 | $41.8M | Sell |
763,356
-16,660
| -2% | -$832K | 0.03% | 162 |
|
|
2025
Q2 | $41.5M | Sell |
780,016
-52,552
| -6% | -$2.67M | 0.03% | 160 |
|
|
2025
Q1 | $36M | Sell |
832,568
-180,159
| -18% | -$9.12M | 0.03% | 154 |
|
|
2024
Q4 | $56.9M | Sell |
1,012,727
-196,774
| -16% | -$12.2M | 0.04% | 140 |
|
|
2024
Q3 | $82.4M | Sell |
1,209,501
-217,116
| -15% | -$12.3M | 0.06% | 126 |
|
|
2024
Q2 | $60.3M | Sell |
1,426,617
-275,371
| -16% | -$15.2M | 0.05% | 134 |
|
|
2024
Q1 | $118M | Sell |
1,701,988
-2,065,067
| -55% | -$131M | 0.09% | 115 |
|
|
2023
Q4 | $279M | Sell |
3,767,055
-299,275
| -7% | -$19.6M | 0.22% | 87 |
|
|
2023
Q3 | $277M | Sell |
4,066,330
-500,751
| -11% | -$42.5M | 0.25% | 79 |
|
|
2023
Q2 | $429M | Sell |
4,567,081
-215,265
| -5% | -$16.8M | 0.36% | 64 |
|
|
2023
Q1 | $324M | Sell |
4,782,346
-148,916
| -3% | -$9.57M | 0.29% | 75 |
|
|
2022
Q4 | $244M | Buy |
4,931,262
+118,025
| +2% | +$4.82M | 0.25% | 81 |
|
|
2022
Q3 | $156M | Buy |
4,813,237
+398,730
| +9% | +$16.4M | 0.16% | 98 |
|
|
2022
Q2 | $174M | Buy |
4,414,507
+55,787
| +1% | +$2.98M | 0.18% | 95 |
|
|
2022
Q1 | $305M | Sell |
4,358,720
-185,274
| -4% | -$13.5M | 0.21% | 87 |
|
|
2021
Q4 | $354M | Buy |
4,543,994
+91,467
| +2% | +$8.07M | 0.19% | 91 |
|
|
2021
Q3 | $425M | Sell |
4,452,527
-13,600
| -0.3% | -$1.44M | 0.22% | 85 |
|
|
2021
Q2 | $555M | Buy |
4,466,127
+119,101
| +3% | +$14.2M | 0.27% | 89 |
|
|
2021
Q1 | $573M | Buy |
4,347,026
+3,197,782
| +278% | +$438M | 0.32% | 79 |
|
|
2020
Q4 | $152M | Buy |
1,149,244
+140,565
| +14% | +$17M | 0.08% | 121 |
|
|
2020
Q3 | $103M | Buy |
1,008,679
+110,518
| +12% | +$9.54M | 0.07% | 121 |
|
|
2020
Q2 | $78.1M | Buy |
898,161
+168,454
| +23% | +$13.5M | 0.06% | 115 |
|
|
2020
Q1 | $42.3M | Buy |
729,707
+9,213
| +1% | +$748K | 0.05% | 119 |
|
|
2019
Q4 | $66.6M | Buy |
720,494
+103,524
| +17% | +$9.1M | 0.06% | 114 |
|
|
2019
Q3 | $55.8M | Sell |
616,970
-94,462
| -13% | -$10.8M | 0.06% | 118 |
|
|
2019
Q2 | $84M | Sell |
711,432
-203,347
| -22% | -$20.5M | 0.09% | 106 |
|
|
2019
Q1 | $79.2M | Buy |
914,779
+30,885
| +3% | +$2.63M | 0.09% | 105 |
|
|
2018
Q4 | $55.8M | Buy |
883,894
+19,765
| +2% | +$1.36M | 0.07% | 111 |
|
|
2018
Q3 | $68.2M | Buy |
864,129
+330,485
| +62% | +$21.6M | 0.07% | 111 |
|
|
2018
Q2 | $31.9M | Buy |
533,644
+171,351
| +47% | +$9.22M | 0.03% | 130 |
|
|
2018
Q1 | $14.6M | Buy |
362,293
+76,342
| +27% | +$3.72M | 0.02% | 159 |
|
|
2017
Q4 | $15M | Buy |
285,951
+26,024
| +10% | +$1.39M | 0.02% | 150 |
|
|
2017
Q3 | $12.2M | Buy |
+259,927
| New | +$10.5M | 0.02% | 149 |
|
Other funds holding EXAS
HI
PCM
FCM
DKCM
Baillie Gifford & Co's EXAS Position: Q4 2025 in Review
Baillie Gifford & Co sold out of Exact Sciences (EXAS) in Q4 2025, closing a stake of 763,356 shares — an estimated $41.8M sold.
Baillie Gifford & Co first reported a position in EXAS in Q3 2017 and held it in 33 quarters. The position peaked at $573M in Q1 2021. 711 funds tracked by Wall St. Rank hold EXAS as of Q4 2025.
- Baillie Gifford & Co reported no remaining Exact Sciences position as of Q4 2025 after selling out during the quarter.
- Baillie Gifford & Co sold 763,356 Exact Sciences shares in Q4 2025, an estimated $41.8M.
- Baillie Gifford & Co first reported a position in Exact Sciences in Q3 2017 and held it in 33 quarters.
- Baillie Gifford & Co's Exact Sciences position peaked at $573M in Q1 2021.
- 711 funds tracked by Wall St. Rank held Exact Sciences as of Q4 2025.
Based on Baillie Gifford & Co's 13F filing for Q4 2025, filed 23 Jan 2026.